Clinical Trials at UCHealth Highlands Ranch Hospital
As of August 2026, 28 paid clinical trials are recruiting at UCHealth Highlands Ranch Hospital, located at 1500 PARK CENTRAL DR, HIGHLANDS RANCH, CO 80129-6687, phone (720) 848-0000 in Highlands Ranch, Colorado. Active studies at this site cover conditions such as Breast Cancer, Anatomic Stage II Breast Cancer AJCC v8 and Muscle Invasive Bladder Urothelial Carcinoma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
28 clinical trials at UCHealth Highlands Ranch Hospital
·Clear filters·Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
The Immune System's Response to Young Women's Breast Cancer
A Novel Patient Decision Aid for Surgical Treatment Options in Early-Stage Breast Cancer
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Common conditions studied in Highlands Ranch
- Breast Cancer (4 active studies)
- Anatomic Stage II Breast Cancer AJCC v8 (3 active studies)
- Muscle Invasive Bladder Urothelial Carcinoma (3 active studies)
- Colorectal Cancer (2 active studies)
- Ovarian Carcinoma (2 active studies)
- Stage II Bladder Cancer AJCC v8 (2 active studies)
Leading research sponsors in Highlands Ranch
- NRG Oncology
- University of Colorado, Denver
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
- Merck Sharp & Dohme LLC
Frequently asked questions
How many paid clinical trials are currently recruiting in Highlands Ranch?
There are approximately 37 recruiting clinical trials in Highlands Ranch, Colorado listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Highlands Ranch pay participants?
Most recruiting trials in Highlands Ranch compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Highlands Ranch?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Highlands Ranch?
The most common conditions under active study in Highlands Ranch include Breast Cancer (4), Anatomic Stage II Breast Cancer AJCC v8 (3), Muscle Invasive Bladder Urothelial Carcinoma (3), Colorectal Cancer (2), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Highlands Ranch?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Highlands Ranch on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Highlands Ranch?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Highlands Ranch?
Recruiting research sites in Highlands Ranch include UCHealth Highlands Ranch Hospital, Highlands Ranch Hospital, Highlands Ranch Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Highlands Ranch right now?
The largest active categories in Highlands Ranch are Cancer & tumors (34), Diabetes & metabolic (1). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of UCHealth Highlands Ranch Hospital?
UCHealth Highlands Ranch Hospital is located at 1500 PARK CENTRAL DR, HIGHLANDS RANCH, CO 80129-6687. Use the Google Maps link in the intro above to get directions.
How do I contact UCHealth Highlands Ranch Hospital?
You can reach UCHealth Highlands Ranch Hospital by phone at (720) 848-0000. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.